According to GuruFocus Insider Data , these are the largest CFO buys during the past week. The overall trend of CFOs is illustrated in the chart below: 



Enservco Corp. ( ENSV ): President and CFO Rick D. Kasch Bought 75,000 Shares 

President and CFO of Enservco Corp. ( ENSV ) Rick D. Kasch bought 75,000 shares on 11/2/2012 at an average price of $0.35. Enservco Corp., formerly known as Asoen Exploration Corp., is engaged in providing oil field services to the companies in the energy sector through its subsidiaries Heat Waves Hot Oil Service and Dillco Fluid Service. Enservco Corp. has a market cap of $7.6 million; its shares were traded at around $0.45 with and P/S ratio of 0.3. 

ENSERVCO reported financial results for its second quarter and six-month period ended 6/30/2012. Second quarter revenue increased 26% to $5.6 million from $4.5 million in last year's second quarter. Revenue through six months increased 10% to $15.2 million from $13.7 million in the same period last year. 

CEO Michael D. Herman and President and CFO Rick D. Kasch bought shares of ENSV stock. 

Delek Logistics ( DKL ): Executive Vice President and CFO Mark B. Cox Bought 25,000 Shares 

Executive vice president and CFO of Delek Logistics ( DKL ) Mark B. Cox bought 25,000 shares on 11/7/2012 at an average price of $21. 

Besides Cox, president and CEO Ezra Uzi Yemin and director Gary M. Sullivan Jr. also bought shares of DKL stock. 

Pixelworks Inc. ( PXLW ): Vice President, CFO and Treasurer Steven L. Moore Bought 22,000 Shares 

Vice president, CFO and treasurer of Pixelworks Inc. ( PXLW ) Steven L. Moore bought 22,000 shares on 11/1/2012 at an average price of $2.35. Pixelworks Inc. designs, develops and markets semiconductors and software that enable the visual display of broadband content through a wide variety of electronic devices. Pixelworks Inc. has a market cap of $43.4 million; its shares were traded at around $2.35 with a P/S ratio of 0.7. 

Pixelworks Inc. announced financial results for the third quarter ended 9/30/2012. Third quarter 2012 revenue was $16.3 million, compared to $15.5 million reported in the prior quarter and $17.4 million in the third quarter of 2011. 

Besides Moore, 10% owner Becker Drapkin Management L.P.[/url], and director [url=http://www.gurufocus.com/InsiderBuy.php?insider=GIBSON+C+SCOTT]C Scott Gibson also bought shares of PXLW stock. 

Genworth Financial Inc. ( GNW ): Acting President and Acting CEO; Senior Vice President and CFO Martin P. Klein Bought 15,000 Shares 

Acting president and acting CEO, and senior vice president and CFO of Genworth Financial Inc. (GNW ) Martin P. Klein bought 15,000 shares on 11/5/2012 at an average price of $6. Genworth Financial is an insurance company in the US. Genworth has a market cap of $2.76 billion; its shares were traded at around $5.61 with a P/E ratio of 8.77 and a P/S ratio of 0.27. 

Genworth Financial, Inc. reported results for the third quarter of 2012. The company reported a net income of $34 million, or $0.07 per diluted share, compared with a net loss of $16 million, or $0.03 per diluted share, in the third quarter of 2011. Net operating income for the third quarter of 2012 was $121 million, or $0.25 per diluted share, compared with net operating income of $62 million, or $0.13 per diluted share, in the third quarter of 2011. 

Besides Klein, director William H. Bolinder, and director James S. Riepe also bought shares of GNW stock. 

Valeant Pharmaceuticals International Inc. ( VRX ): Executive Vice President and CFO Howard Bradley Schiller Bought 18,300 Shares 

Executive vice president and CFO of Valeant Pharmaceuticals International Inc. ( VRX ) Howard Bradley Schiller bought 18,300 shares on 11/6/2012 at an average price of $54.10. Valeant Pharmaceuticals International Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant Pharmaceuticals has a market cap of $16.9 billion; its shares were traded at around $53.96 with a P/E ratio of 15.2 and P/S ratio of 6.9. 

Valeant Pharmaceuticals International Inc. announced third quarter financial results for 2012 and reported a total revenue of $884 million. 

Besides Schiller, executive vice president, administration and chief human capital officer Brian M. Stolz, and director Lloyd Mitchell Segal bought shares of VRX stock. 

For the complete list of stocks that bought by their CFOs, go to: Insider Buys.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .